Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Advances and unmet needs for breast cancer

Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, discusses recent advances and remaining unmet needs in breast cancer. Dr Gluz talks on promising developments in HR+ HER2- breast cancer, including results from the RxPONDER trial (NCT01272037), as well as advances in personalised treatment for patients with HER2+ breast cancer. Dr Gluz also discusses the unmet needs in for patients with premenopausal or triple-negative breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.